Two Months Bring Two New Treatments for the APF Community!

With the FDA's approval last month of SCENESSE® and yesterday of GIVLAARI (Givosiran), along with the longstanding approval of Panhematin, the Porphyria community has experienced great success for viable treatment options. As we move into this season of gratitude, we can declare 2019 a victory for Porphyria patients, and the outlook for 2020 is even better as we look forward to the implementation of these treatments.